2019 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and the European AIDS Conference*

Download All
IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Review the latest findings relevant to HIV care from 3 important international meetings.


Capsule Summary Slidesets

In patients receiving first-line doravirine, median weight gain over 96 weeks was 1.5 kg, a change similar to that seen in adults without HIV infection and in those starting ART with other agents.

Released: November 18, 2019

Among cis-MSM and transgender women at high risk of HIV infection, initiation of daily oral FTC/TAF for PrEP associated with significantly better BMD, eGFR, and renal tubular function, as measured by urine RBP:Cr and β2M:Cr.

Released: November 19, 2019

The contribution of PrEP to decline in HIV incidence was 2.1 times larger than treatment as prevention in an analysis considering both interventions.

Released: October 29, 2019

Final analysis of this phase IIb study observes that oral cabotegravir plus rilpivirine maintenance regimen provides durable virologic suppression.

Released: November 18, 2019

Among patients initiating dual therapy, virologic suppression rates maintained regardless of stratification by age, sex, race, and baseline HIV-1 RNA level or CD4+ cell count.

Released: October 31, 2019

Prospective data on birth outcomes demonstrate no increase in rates of spontaneous abortions, stillbirths, neural tube defects, or other congenital anomalies with raltegravir use at conception or during pregnancy.

Released: November 18, 2019

No patient met criteria for protocol-defined virologic failure or discontinued for lack of efficacy through Week 48.

Released: October 29, 2019

This small prospective study found that sizeable proportions of MSM (24% to 35%) experienced more than 3% BMD loss in the femur, spine, and hip after 2 years of TDF-based PrEP.

Released: November 19, 2019

Switching from a TAF-based regimen to DTG/3TC maintains virologic suppression across patient subgroups regardless of patient demographics, disease characteristics, or baseline third agent.

Released: November 8, 2019

In pooled analysis of 373 treatment-naive and virologically suppressed females, no emergent resistance or discontinuation for renal or bone adverse events was observed.

Released: November 20, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings